In comparison to HDAC pan-inhibitors, the subtype-selective HDAC inhibitor tucidinostat decrease and functionally inhibit the expansion of Treg and MDSC to overcome immune-suppressive tumor microenvironment (Que et al., 2021; Chen et al., 2022). Here, HDAC9 is linked to neoplasm.